Climate Drugs Health

Asia migration deaths highest in the world at 2,515 people: IOM 

HQ Team Wednesday 26, 2025: At least 2,515 people were killed along the perilous migration routes in Asia last year, making it the.

Read More
Drugs Health Pharma

Merck signs $2b licensing deal with Jiangsu Hengrui for heart disease drug

HQ Team March 25, 2025: Merck & Co., Inc. has bought global rights for an experimental oral drug to treat heart diseases from.

Read More
Drugs Health Research

Plant-based foods may help you live without chronic diseases until 70

HQ Team March 25, 2025: A diet rich in plant-based foods during midlife, with a lower intake of ultra-processed and moderate animal-based foods.

Read More
Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

Read More
Drugs Health Pharma

Funding cuts ‘severely’ bleeding UN’s child survival, stillbirth programs

HQ Team March 25, 2025: Progress in slowing child mortality and stillbirth deaths has received a severe blow due to global funding cuts.

Read More
Drugs Pharma

Brazil’s pharma giant Hypera to launch generic Ozempic in 2026

Bharti Jayshankar March 24, 2025: Brazilian pharmaceutical giant Hypera announced plans to introduce a generic version of semaglutide—the active ingredient in Novo Nordisk’s.

Read More
Drugs Research

Study uncovers protein’s dual role in sepsis, offering new treatment hope

HQ Team March 18, 2025: Sepsis, a life-threatening response to infection that triggers organ failure, claims over 11 million lives worldwide annually, according.

Read More
Drugs Health

Abrupt cessation of US funds could lead to 3 million HIV-related deaths: WHO

HQ Times March 18, 2025: The strides made in disease containment and eradication such as malaria, HIV, and tuberculosis in the last 20.

Read More
Drugs Research

Celon Pharma’s pill shows promise in reducing dyskinesia in Parkinson’s trial

HQ Team March 17, 2025: Celon Pharma’s human trial with PDE10A inhibitor, CPL’36, has achieved statistically significant reductions in involuntary movements caused by.

Read More
Drugs

Eneboparatide succeeds in Phase III trial for chronic hypoparathyroidism

HQ Team March 17, 2025: The Phase III CALYPSO trial, led by Alexion, AstraZeneca Rare Disease, has shown promising results for eneboparatide (AZP-3601),.

Read More